Galectin Therapeutics Says FDA Alignment Reached on Phase 3 Belapectin Trial

MT Newswires Live06-23

Galectin Therapeutics (GALT) said Tuesday it has reached an agreement with the US Food and Drug Administration on the key elements of a phase 3 trial of belapectin in metabolic dysfunction-associated steatohepatitis cirrhosis and portal hypertension.

The company said the regulator agreed during a type C meeting to a composite liver outcome, including prevention of development of large esophageal varices, as primary endpoint, and accepted the proposed blinded central review process for endoscopic assessment of esophageal varices.

Galectin said it plans to assess a single 2 mg dose of belapectin in the study and file its phase 3 protocol in Q3.

The company added that it is seeking strategic and financial partnerships to support development and commercialization.

Shares of the company were down 9% in premarket activity Tuesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment